Protara Therapeutics
Nasdaq TARA · New York, NY
Works in Genetic & rare · GI & liver · Hematology · Metabolic & endocrine · Oncology · Renal & urogenital · Women's health
Protara Therapeutics is a clinical trial sponsor based in New York, NY, listed as Nasdaq TARA. It has 4 active clinical trials with 582 planned participants, across 7 therapeutic areas. Since 2021 it has completed 3 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq TARA
Fundraising
Pipeline · 4 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Protara Therapeutics
Protara Therapeutics is lead sponsor of 4 active clinical trials on ClinicalTrials.gov, with 582 planned participants, in Genetic & rare, GI & liver, Hematology, Metabolic & endocrine and other areas. Since 2021 it has completed 3 trials and stopped 0 early.
Protara Therapeutics is based in New York, NY and is listed as Nasdaq TARA. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Protara Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-06.
Approve Suite is not affiliated with Protara Therapeutics. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.